|
業務類別
|
-- |
|
業務概覽
|
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline. |
| 公司地址
| Centralbahnstrasse 4, Basel, CHE, 4051 |
| 電話號碼
| +41 613241111 |
| 傳真號碼
| +41 613248001 |
| 公司網頁
| https://www.sandoz.com |
| 員工數量
| 23567 |
| Mr. Michael Rechsteiner |
Independent Director |
25/02/2026 |
| Mr. Graeme Pitkethly |
Independent Director |
25/02/2026 |
| Dr. Mathai Mammen, M.D.,PhD |
Independent Director |
25/02/2026 |
| Mr. Gilbert Ghostine |
Chairman of the Board |
25/02/2026 |
| Ms. Maria Rosaria Varsellona |
Independent Director |
25/02/2026 |
| Dr. Shamiram R. Feinglass, M.D. |
Independent Director |
25/02/2026 |
| Mr. Yannis Skoufalos |
Independent Director |
25/02/2026 |
| Ms. Aarti S. Shah |
Independent Director |
25/02/2026 |
| Mr. Urs Riedener |
Independent Director |
25/02/2026 |
| Dr. Karen J. Huebscher, PhD |
Vice Chairman of the Board |
25/02/2026 |
|
|
|
|
